RIPA Lysis and Extraction Buffer

<strong>RIPA Lysis and Extraction Buffer</strong>_x000D_ <table width="1028">_x000D_ <tbody>_x000D_ <tr>_x000D_ <td width="285">Catalog number:</td>_x000D_ <td width="743">B2010077</td>_x000D_ </tr>_x000D_ <tr>_x000D_ <td>Lot number:</td>_x000D_ <td>Batch Dependent</td>_x000D_ </tr>_x000D_ <tr>_x000D_ <td>Expiration date:</td>_x000D_ <td>Batch Dependent</td>_x000D_ </tr>_x000D_ <tr>_x000D_ <td>Volume/Weight</td>_x000D_ <td>100 mL</td>_x000D_ </tr>_x000D_ <tr>_x000D_ <td>pH</td>_x000D_ <td>7.6</td>_x000D_ </tr>_x000D_ <tr>_x000D_ <td>Supplied as</td>_x000D_ <td>Ready-to-use 1X solution</td>_x000D_ </tr>_x000D_ <tr>_x000D_ <td>Appearance</td>_x000D_ <td>Clear solution</td>_x000D_ </tr>_x000D_ <tr>_x000D_ <td>Applications</td>_x000D_ <td>Efficient and rapid lysis of various types of cells (including mammalian cells). The buffer is useful for extracting proteins from the cytoplasme and the nucleus as well as various cellular membranes. This buffer is compatible with most protein purification and assaying protocols.</td>_x000D_ </tr>_x000D_ <tr>_x000D_ <td>Shelf-Life</td>_x000D_ <td>2 years from date of manufacture</td>_x000D_ </tr>_x000D_ <tr>_x000D_ <td>Storage:</td>_x000D_ <td>Keep at 2-8¬∞C</td>_x000D_ </tr>_x000D_ <tr>_x000D_ <td>Keywords:</td>_x000D_ <td>RIPA Buffer, RIPA Lysis Buffer, RIPA Extraction Buffer</td>_x000D_ </tr>_x000D_ <tr>_x000D_ <td>Grade</td>_x000D_ <td>Biotechnology grade. All components are highly pure (minimum 99%). All solutions are made with Type I ultrapure water (resistivity >18 MŒ©-cm) and are filtered on a 0.22 um.</td>_x000D_ </tr>_x000D_ <tr>_x000D_ <td>References Related to RIPA Lysis Buffer</td>_x000D_ <td width="743">1: de Fries RU, Golub SH. Characteristics and mechanism of IFN-gamma-induced_x000D_ protection of human tumor cells from lysis by lymphokine-activated killer cells._x000D_ J Immunol. 1988 May 15;140(10):3686-93.2: Thiele DL, Lipsky PE. Tumor cell lysis by T cells distinct from NK cells and_x000D_ alloantigen-specific cytotoxic T cells. Clin Immunol Immunopathol. 1988_x000D_ Dec;49(3):405-23.3: Collins JL, Kao MS. The anticancer drug, cisplatin, increases the naturally_x000D_ occurring cell-mediated lysis of tumor cells. Cancer Immunol Immunother._x000D_ 1989;29(1):17-22.4: Manning LS, Bowman RV, Darby SB, Robinson BW. Lysis of human malignant_x000D_ mesothelioma cells by natural killer (NK) and lymphokine-activated killer (LAK)_x000D_ cells. Am Rev Respir Dis. 1989 Jun;139(6):1369-74._x000D_ _x000D_ 5: Bean P, Mazumder A. Resistance of different tumor cells to lysis by_x000D_ lymphokine activated killer cells can be mediated by distinct mechanisms._x000D_ Immunobiology. 1992 Jun;185(1):63-77._x000D_ _x000D_ 6: Kondo S, Miyatake S, Kikuchi H, Oda Y, Iwasaki K, Ohyama K, Namba Y._x000D_ Mechanism of interferon gamma-induced protection of human gliosarcoma cells from_x000D_ lymphokine-activated killer lysis: division of lymphokine-activated killer cells_x000D_ into natural killer- and T-like cells. Neurosurgery. 1992 Sep;31(3):534-40._x000D_ _x000D_ 7: Borysiewicz LK, Rodgers B, Morris S, Graham S, Sissons JG. Lysis of human_x000D_ cytomegalovirus infected fibroblasts by natural killer cells: demonstration of_x000D_ an interferon-independent component requiring expression of early viral proteins_x000D_ and characterization of effector cells. J Immunol. 1985 Apr;134(4):2695-701._x000D_ _x000D_ 8: Fresa KL, Karjalainen HE, Tevethia SS. Sensitivity of simian virus_x000D_ 40-transformed C57BL/6 mouse embryo fibroblasts to lysis by murine natural_x000D_ killer cells. <a href="https://pubmed.ncbi.nlm.nih.gov/3027174/">J Immunol.</a> 1987 Feb 15;138(4):1215-20.</td>_x000D_ </tr>_x000D_ <tr>_x000D_ <td>Related Products</td>_x000D_ <td><a href="https://moleculardepot.com/product-category/buffers/">Biochemical Buffers and Solutions</a></td>_x000D_ </tr>_x000D_ </tbody>_x000D_ </table>